News

The company has reported a net income was $6.48m, or $0.02 per diluted share, compared to a net loss of $3.15m, or $0.02 loss per diluted share, for

The study results suggested that the adult patients evaluated with Cimzia that achieved early responses were found to have an increased chance of achieving longer-term outcomes. In the

The company has reported a net loss of $1.38m, or $0.02 loss per diluted share, compared to net loss of $1.61m or $0.02 loss per diluted share, for

SimpleCTMS is intended to offer the benefits of a CTMS (Clinical Trial Management System) without the extensive upfront financial and resource commitments associated with traditional enterprise systems or

The company has reported a net loss of $11.6m, or $0.24 loss per diluted share, compared to a net loss of $14.08m, or $0.30 loss per diluted share,

Valentine will succeed James Conway, who is retiring after 15 years as CEO at Netsmart. Prior to Netsmart, Valentine worked for Cerner Corporation as the executive vice president

The company has reported a net loss of $7.45m, or $0.07 loss per diluted share, compared to net loss of $10.34m or $0.10 loss per diluted share, for

The companies are expected to investigate the effects of the drug without a background of medical or surgical castration. Astellas and Medivation intend to recruit around 60 patients

rFIXFc is a recombinant Factor IX Fc fusion protein developed using monomeric Fc fusion technology. It is a clotting factor designed to replace the protein that hemophilia B